Spots Global Cancer Trial Database for ice
Every month we try and update this database with for ice cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| ODSH + ICE Chemotherapy in Pediatric Solid Tumors | NCT02164097 | Recurrent Solid... Refractory Soli... Sarcoma Wilms' Tumor Neuroblastoma | ODSH | 1 Year - 21 Years | New York Medical College | |
| A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | NCT00283439 | Chemotherapy-In... Hodgkin's Lymph... Non-Hodgkin's L... Cancer Oncology Thrombocytopeni... | AMG 531 | 18 Years - | Amgen | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | NCT05464329 | Diffuse Large B... High-grade B-ce... Transformed B-C... Follicular Lymp... | Mosunetuzumab DHAX ICE | 18 Years - | Washington University School of Medicine | |
| Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma | NCT00439361 | Hodgkin Lymphom... Lymphoma | Bortezomib Carboplatin Etoposide Ifosfamide Mesna | 16 Years - | M.D. Anderson Cancer Center | |
| A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma | NCT00117455 | Non-Hodgkin's L... | pegfilgrastim filgrastim | 18 Years - | Amgen | |
| Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL | NCT00588094 | Lymphoma B-cell Non-Hodg... | Rituximab, Ifos... | 18 Years - 72 Years | Memorial Sloan Kettering Cancer Center | |
| A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma | NCT00117455 | Non-Hodgkin's L... | pegfilgrastim filgrastim | 18 Years - | Amgen | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | NCT05464329 | Diffuse Large B... High-grade B-ce... Transformed B-C... Follicular Lymp... | Mosunetuzumab DHAX ICE | 18 Years - | Washington University School of Medicine | |
| Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL | NCT00588094 | Lymphoma B-cell Non-Hodg... | Rituximab, Ifos... | 18 Years - 72 Years | Memorial Sloan Kettering Cancer Center | |
| Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | NCT01169636 | Hodgkin's Lymph... | Panobinostat Ifosfamide Mesna Carboplatin Etoposide Pegfilgrastim | 16 Years - | M.D. Anderson Cancer Center | |
| Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) | NCT00823719 | Lymphoma, Large... | ofatumumab + IC... ofatumumab + DH... | 18 Years - | GlaxoSmithKline | |
| Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | NCT01169636 | Hodgkin's Lymph... | Panobinostat Ifosfamide Mesna Carboplatin Etoposide Pegfilgrastim | 16 Years - | M.D. Anderson Cancer Center | |
| A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | NCT00283439 | Chemotherapy-In... Hodgkin's Lymph... Non-Hodgkin's L... Cancer Oncology Thrombocytopeni... | AMG 531 | 18 Years - | Amgen | |
| Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) | NCT00823719 | Lymphoma, Large... | ofatumumab + IC... ofatumumab + DH... | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
